Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for OCGN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2013. Start Trial.
Date Value
June 30, 2026 -12.20M
March 31, 2026 -21.79M
December 31, 2025 -13.96M
September 30, 2025 -12.92M
June 30, 2025 -10.73M
March 31, 2025 -19.36M
December 31, 2024 -10.36M
September 30, 2024 -11.27M
June 30, 2024 -9.911M
March 31, 2024 -10.60M
December 31, 2023 -11.30M
September 30, 2023 -13.71M
June 30, 2023 -18.81M
March 31, 2023 -18.24M
December 31, 2022 -16.91M
September 30, 2022 -14.30M
June 30, 2022 -13.80M
March 31, 2022 -15.07M
December 31, 2021 -12.80M
September 30, 2021 -8.053M
June 30, 2021 -21.80M
March 31, 2021 -5.283M
December 31, 2020 -4.282M
September 30, 2020 -2.654M
June 30, 2020 -3.086M
Date Value
March 31, 2020 -4.686M
December 31, 2019 -8.744M
September 30, 2019 -2.118M
June 30, 2019 -3.364M
March 31, 2019 -2.667M
December 31, 2018 -2.786M
September 30, 2018 -6.918M
June 30, 2018 -5.213M
March 31, 2018 3.286M
December 31, 2017 -4.319M
September 30, 2017 -5.727M
June 30, 2017 -5.629M
March 31, 2017 -7.345M
December 31, 2016 -5.893M
September 30, 2016 -5.459M
June 30, 2016 -6.543M
March 31, 2016 -7.841M
December 31, 2015 -6.997M
September 30, 2015 -6.882M
June 30, 2015 -7.466M
March 31, 2015 -8.689M
December 31, 2014 -5.145M
September 30, 2014 -2.795M
June 30, 2014 -5.446M
March 31, 2014 -5.019M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
CytomX Therapeutics, Inc. -18.07M
ACADIA Pharmaceuticals, Inc. 100.78M
Biogen, Inc. 448.90M
Gilead Sciences, Inc. 3.573B
MannKind Corp. -18.63M